NCT04992832View on ClinicalTrials.gov

Multi-intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Heart Failure With Reduced Ejection Fraction（PRIME-HFrEF Study）

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

January 17, 2023

Study Completion Date

April 4, 2023

Conditions
Heart Failure, Systolic
Interventions
BIOLOGICAL

human umbilical cord mesenchymal stem cells

Human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group.

OTHER

human serum albumin

Saline solution containing 1 percent human serum albumin will be infused to the control group.

Trial Locations (1)

Unknown

Heart Failure Department, East Hospital Affiliated to Tongji University, Shanghai

All Listed Sponsors
lead

Shanghai East Hospital

OTHER

NCT04992832 - Multi-intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Heart Failure With Reduced Ejection Fraction（PRIME-HFrEF Study） | Biotech Hunter | Biotech Hunter